可注射自组装的普罗胺纳米球,用于有效治疗关节炎
Guangjie Li1,2, Fei He2, Jianbao Feng3
1The First Hospital of Lanzhou University, Lanzhou, Gansu Province, People's Republic of China.
International journal of nanomedicine
|February 3, 2025
概括
新的Procyanidin (PA) 纳米球显示了骨关节炎 (OA) 修复的前景. 这些可注射的纳米球增强了细胞活力,促进了软骨的修复,为OA提供了一个新的治疗策略.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术 纳米技术
- 骨关节炎研究 骨关节炎研究
背景情况:
- 骨关节炎 (OA) 是一种广泛的关节疾病,严重影响患者的移动性和生活质量.
- 目前的OA治疗方法,主要是止痛药和抗炎药,具有有限的治疗效益.
- 迫切需要创新的治疗方法来解决OA的潜在病理问题.
研究的目的:
- 为增强骨关节炎 (OA) 治疗开发可注射的普亚尼丁 (PA) 纳米球.
- 为了研究用Pluronic F127 (PF127) 合成生物相容的纳米球的公素 (PAs) 的自我组装.
- 在OA的细胞和动物模型中评估PA纳米球的治疗潜力.
主要方法:
- 普罗亚尼丁 (PA) 通过结合与Pluronic F127 (PF127) 自组合,形成可注射的纳米球.
- 在L929纤维细胞和ADTC5红细胞上进行了细胞活力测试.
- 在接受治疗的细胞中分析了原蛋白和甘氨酸糖的蛋白质表达.
- 用一种酶解诱导的老鼠OA模型来评估PA纳米球体的体内疗效.
主要成果:
- 与未组装的PA相比,PA纳米球显著提高了纤维细胞和肌体细胞的细胞活力.
- 自组装的PA/PF127纳米球促进了纤维细胞中的原蛋白合成和细胞中的糖氨基甘氨酸/原IIA1型表达.
- 在大鼠OA模型中,PA/PF127纳米球降低了关节胀,加速了下骨和软骨表面的形成.
- 这些发现表明细胞水平OA修复的潜力.
结论:
- 新型PA/PF127纳米球显示出骨关节炎 (OA) 修复的巨大潜力.
- 自组装方法产生可注射,生物相容的纳米结构,具有治疗效益.
- 这项研究为开发用于治疗OA的先进纳米药物提供了宝贵的见解.
相关概念视频
Skeletal Muscle Relaxants: Therapeutic Uses
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...
Peripherally and Centrally Acting Muscle Relaxants: A Comparison
Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic drugs,...
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic drugs,...
Centrally Acting Muscle Relaxants: Therapeutic Uses
Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system.
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
Drug Delivery: Miscellaneous Routes
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...


